secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107277
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q2 net loss $25.9M; cash runway into Q1 2027; CD47 biomarker data highlights evorpacept potential
--------------------------------------------------------------------------------

- GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.
- Cash, equivalents & investments $83.5M; runway extended into Q1 2027 after pausing ASPEN-CRC trial.
- ASPEN-06 analysis: CD47-high HER2+ gastric cancer patients had 65% ORR with evorpacept + TRP vs 26% TRP alone; full data Q4 2025.
- ASPEN-Breast amended to single-arm biomarker-driven study; interim data expected Q3 2026.
- ALX2004 Phase 1 first patient dosing in August 2025; initial safety data 1H2026. Allison Dillon appointed COO; Daniel Curran appointed to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/0000950170-25-107277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/alxo-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer